TWI358290B - Topical nepafenac formulations - Google Patents

Topical nepafenac formulations Download PDF

Info

Publication number
TWI358290B
TWI358290B TW094141182A TW94141182A TWI358290B TW I358290 B TWI358290 B TW I358290B TW 094141182 A TW094141182 A TW 094141182A TW 94141182 A TW94141182 A TW 94141182A TW I358290 B TWI358290 B TW I358290B
Authority
TW
Taiwan
Prior art keywords
composition
group
patent application
carbomer
preservative
Prior art date
Application number
TW094141182A
Other languages
English (en)
Other versions
TW200626132A (en
Inventor
Warren Wong
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35848959&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI358290(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of TW200626132A publication Critical patent/TW200626132A/zh
Application granted granted Critical
Publication of TWI358290B publication Critical patent/TWI358290B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

第94141182號專利申諳案說明書暨申請專利範圍修正本修正曰期·· 100年丨丨月30曰 代表。、? 奈帕芬胺為一種已知化合物。可以數種已知方法製備 。請見’如’美國專利號5,475,034與4,313,949。本發明組 成物含有0.09-0.11%奈帕芬胺,較佳為〇1%奈帕芬胺。 除了奈帕芬胺之外,本發明之懸浮液組成物亦含有卡 波姆(carbomer) ’作為增稠劑或生理穩定性_增強劑。適用 於本發明之卡波姆(carbomer)亦已知為“羧基乙烯基聚合物 或缓基聚甲稀。為商業上可購得’如購自Noveon,Inc. (Cleveland,Ohi〇) ’ 此產品之商標名稱為 Carb〇p〇1®。Carb〇p〇1 聚合物為交聯性、含丙烯酸-聚合物。其係與丙烯基蔗糖或 烯丙基季戊四醇交聯。Carbopol聚合物為丙烯酸之聚合物, 經匸他川烷基丙烯酸酯修飾,並與烯丙基季戊四醇交聯。用 於本發明中之較佳卡波姆(carb〇mer)為與丙烯基蔗糖或烯 丙基季戊四醇交聯之丙烯酸聚合物,商品名稱為Carb〇p〇1® 974P。本發明組成物中卡波姆(carbomer)之濃度範圍通常為 0.4 — 0.6 %,較佳為〇 5 〇/〇。 本發明組成物亦含有眼科上可接受之非離子性界面活 性劑。許多眼科上可接受之非離子性界面活性劑為已知。 適用之非離子性界面活性劑包括,但不侷限於,泰洛沙伯 (tyloxapol);聚氧基乙烯基山梨醣酯,如聚山梨醣酯如聚 山梨醣酯60與聚山梨醣酯8〇 ;聚乙氧基化蓖麻油如 CremophorEL;聚乙氧基化氫化蓖麻油,如Hc〇 4〇以及 伯洛沙姆(P〇l〇xamers)。最佳之界面活性劑為泰洛沙伯 (tyloxapol)。若為泰洛沙伯(tyl〇xap〇1),該界面活性劑一般

Claims (1)

1358290 第94141182號專利申請案說明書暨申請專利範100年11月30曰 十、申請專利範圍:1^511 1. 一種可局部投藥之眼科用組成物,由下列組ik h a) 0.09-0.1i%(w/v)奈帕芬胺; b) 0_4 - 0.6% (w/v)卡波姆(carbomer); c) 一非離子性界面活性劑; d) —滲透強度-調整試劑,其量足以使該組成物具 250 - 350 mOsm/kg之渗透度; e) — pH-調整試劑,其量足以使該組成物具7.0-7.8 之pH值;以及 f) 水, 其中該組成物選擇性地包含一成份,選自於由防腐 劑與螯合劑組成之族群。 2. 如申請專利範圍第1項之組成物,其中該組成物含有 0.1% (w/v)奈帕芬胺。 3_如申請專利範圍第1項之組成物,其中該組成物含有 0.5% (w/v)卡波姆(carbomer)。 4. 如申請專利範圍第1項之組成物,其中該卡波姆 (carbomer)為一丙稀酸與稀丙基蔗糖或烯丙基季戊四醇 交聯之聚合物。 5. 如申請專利範圍第1項之組成物,其中該非離子性界面 活性劑為泰洛沙伯(tyloxapol)。 6. 如申請專利範圍第5項之組成物,其中該組成物包含 0.01% (w/v)泰洛沙伯’(tyloxapol)。 7. 如申請專利範圍第1項之組成物,其中該滲透強度-調整 13 1358290 第州侧2號專利申請案說明書暨申請專利範圍修正本修正 曰期:100年11月3〇 試劑係選自於由金屬氣化鹽與甘 8.如申請專利範圍第7項之組成物, 試劑包含氣化鈉與甘露醇。 曰 露醇組成之族群。 其中該滲透強度-調整 9.如申請專利範圍第8項之組成物,其中該組成物係包含 0‘3 - 0.5% (w/v)氯化鈉與2 _ 3% (w/v)甘露醇。 K)·如申請專職圍第9項之組成物,其中該组成物係包含 0.4% (w/ν)氯化鈉與2_4% (w/v)甘露醇。 11_如申請專利範圍第丨項之組成物,其#該pH調整試劑係 選自於由氫氣酸與氫氧化鈉組成之族群。 12·如申請專利·第丨項之組成物,其中肋成物之阳值 為 7·3 — 7·7。 13.如申請專利範圍第1項之組成物’其中該組成物含有防 腐劑與螫合劑二者。 14·如申請專利範圍第1項之組成物,其中該防腐劑係選自 於由鹵化苄二甲烴銨(benzaik〇nium halides);聚季銨鹽 -l(P〇lyquaternium-l);以及二氧化氯組成之族群。 15·如申請專利範圍第1項之組成物,其中該防腐劑為氣化 一 甲煙敍(benzalkonium chloride)。 16.如申請專利範圍第15項之組成物,其中該組成物包含 0.005%氣化苄二甲烴銨。 17.如申請專利範圍第1項之組成物,其令該螫合劑係選自 於由依地酸二鈉鹽;依地酸三鈉鹽;依地酸四鈉鹽;以 及二伸乙基胺五醋酸鹽(diethyleneamine pentaacetate)組 成之族群。 14 1358290 第94141182號專利申請案說明書暨申請專利範圍修正本修正日期:100年11月30曰 18. 如申請專利範圍第17項之組成物,其中該組成物包含 0.001 - 0.1% (w/v)依地酸二鈉鹽。 19. 如申請專利範圍第1項之組成物,用於治療一病患眼部 發炎病症。 20. —種可局部投藥之眼科用組成物,由下列組成 a) 0.1%(w/v)奈帕芬胺; b) 0.5% (w/v)卡波姆(carbomer); c) 0.01%(w/v)泰洛沙伯(tyloxapol); d) 0.4% (w/v)氣化鈉; e) 2.4%(w/v)甘露醇; f) 一pH-調整試劑,其量足以使該組成物具7.3 -7.7 之pH值; g) 0.0〇5% (w/v)氯化苄二曱烴銨; h) 0.01%依地酸二鈉;以及 i) 純水。 15
TW094141182A 2004-12-02 2005-11-23 Topical nepafenac formulations TWI358290B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63256204P 2004-12-02 2004-12-02

Publications (2)

Publication Number Publication Date
TW200626132A TW200626132A (en) 2006-08-01
TWI358290B true TWI358290B (en) 2012-02-21

Family

ID=35848959

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094141182A TWI358290B (en) 2004-12-02 2005-11-23 Topical nepafenac formulations

Country Status (24)

Country Link
US (3) US7834059B2 (zh)
EP (1) EP1819362B1 (zh)
JP (2) JP4968844B2 (zh)
KR (1) KR101289661B1 (zh)
CN (1) CN101068573A (zh)
AR (1) AR052252A1 (zh)
AT (1) ATE476200T1 (zh)
AU (1) AU2005311738B2 (zh)
BR (1) BRPI0518904B1 (zh)
CA (1) CA2586807C (zh)
CY (1) CY1110780T1 (zh)
DE (1) DE602005022756D1 (zh)
DK (1) DK1819362T3 (zh)
ES (1) ES2348249T3 (zh)
HK (1) HK1104225A1 (zh)
MX (1) MX2007006558A (zh)
PL (1) PL1819362T3 (zh)
PT (1) PT1819362E (zh)
RU (1) RU2007124638A (zh)
SI (1) SI1819362T1 (zh)
TW (1) TWI358290B (zh)
UY (1) UY29238A1 (zh)
WO (1) WO2006060618A2 (zh)
ZA (1) ZA200704763B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US20060257487A1 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
EP1906916B1 (en) * 2005-05-10 2008-10-29 Alcon Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
US20080057022A1 (en) * 2006-08-30 2008-03-06 Erning Xia Ophthalmic Pharmaceutical Compositions and Uses Thereof
CA2687717A1 (en) * 2007-05-24 2008-12-18 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
TWI531362B (zh) * 2008-07-21 2016-05-01 艾爾康股份有限公司 具有治療劑遞送能力之眼科裝置
TW201023912A (en) 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
WO2010101971A1 (en) * 2009-03-03 2010-09-10 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
WO2010101989A1 (en) * 2009-03-03 2010-09-10 Alcon Research, Ltd. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2011068872A2 (en) 2009-12-03 2011-06-09 Alcon Research, Ltd. Carboxyvinyl polymer-containing nanoparticle suspension
US9532222B2 (en) 2010-03-03 2016-12-27 Duo Security, Inc. System and method of notifying mobile devices to complete transactions after additional agent verification
US9544143B2 (en) 2010-03-03 2017-01-10 Duo Security, Inc. System and method of notifying mobile devices to complete transactions
US9467463B2 (en) 2011-09-02 2016-10-11 Duo Security, Inc. System and method for assessing vulnerability of a mobile device
AU2012351948A1 (en) * 2011-12-16 2014-07-10 Allergan, Inc. Ophthalmic compositions comprising polyvinyl capralactam - polyvinyl acetate - polyethylene glycol graft copolymer
EP3013790A1 (en) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Process for the preparation of nepafenac
CN104490861A (zh) * 2014-11-21 2015-04-08 三明欣茂药业有限公司 一种缓释型奈帕芬胺眼用制剂
EP3470059B1 (en) 2015-01-26 2020-04-01 Bausch & Lomb Incorporated Ophthalmic suspension composition
US9930060B2 (en) 2015-06-01 2018-03-27 Duo Security, Inc. Method for enforcing endpoint health standards
CN107024550A (zh) * 2016-12-21 2017-08-08 广州仁恒医药科技股份有限公司 奈帕芬胺眼用药物组合物的质控方法
CN106963730A (zh) * 2016-12-22 2017-07-21 广州仁恒医药科技股份有限公司 高度稳定的奈帕芬胺眼用药物组合物
US10412113B2 (en) 2017-12-08 2019-09-10 Duo Security, Inc. Systems and methods for intelligently configuring computer security
US11658962B2 (en) 2018-12-07 2023-05-23 Cisco Technology, Inc. Systems and methods of push-based verification of a transaction
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
CN114272207B (zh) * 2022-01-21 2023-04-11 山东诺明康药物研究院有限公司 一种纳米晶混悬滴眼液及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226344A (zh) 1967-07-31 1971-03-24
SE400966B (sv) 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
US4313949A (en) 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en) 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
US4503073A (en) 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
US4568695A (en) 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
DE3668450D1 (de) 1985-03-14 1990-03-01 Smithkline Dauelsberg 5-aminosalicylsaeurederivate von nicht-steroidalen entzuendungshemmenden sauren.
US4851443A (en) 1985-03-14 1989-07-25 Smith Kline Dauelsberg, Gmbh Carboxylic acid amides, compositions and medical use thereof
US4683242A (en) 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US4910225A (en) 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US5461081A (en) 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5624893A (en) 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US5475034A (en) 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
AR030346A1 (es) 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
AR030345A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
JP2005525408A (ja) 2002-05-03 2005-08-25 アルコン,インコーポレイテッド アンフェナクまたはネパフェナクを用いる血管内皮増殖因子媒介性血管障害の処置方法
JP4500261B2 (ja) 2003-01-21 2010-07-14 千寿製薬株式会社 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性液剤
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations

Also Published As

Publication number Publication date
HK1104225A1 (en) 2008-01-11
CN101068573A (zh) 2007-11-07
WO2006060618A3 (en) 2006-10-19
US20120029084A1 (en) 2012-02-02
JP2008521926A (ja) 2008-06-26
PL1819362T3 (pl) 2010-12-31
WO2006060618A2 (en) 2006-06-08
US7834059B2 (en) 2010-11-16
AU2005311738A1 (en) 2006-06-08
JP4968844B2 (ja) 2012-07-04
SI1819362T1 (sl) 2010-10-29
RU2007124638A (ru) 2009-01-10
JP2012041368A (ja) 2012-03-01
MX2007006558A (es) 2007-06-15
CY1110780T1 (el) 2015-06-10
ES2348249T3 (es) 2010-12-02
ATE476200T1 (de) 2010-08-15
AR052252A1 (es) 2007-03-07
EP1819362B1 (en) 2010-08-04
US8324281B2 (en) 2012-12-04
UY29238A1 (es) 2006-05-31
TW200626132A (en) 2006-08-01
PT1819362E (pt) 2010-10-11
AU2005311738B2 (en) 2011-02-03
BRPI0518904B1 (pt) 2023-01-24
EP1819362A2 (en) 2007-08-22
DK1819362T3 (da) 2010-10-18
ZA200704763B (en) 2008-09-25
CA2586807A1 (en) 2006-06-08
DE602005022756D1 (de) 2010-09-16
BRPI0518904A2 (pt) 2008-12-16
US20110015271A1 (en) 2011-01-20
KR101289661B1 (ko) 2013-07-29
KR20070089687A (ko) 2007-08-31
US20060122277A1 (en) 2006-06-08
CA2586807C (en) 2013-01-29
US8071648B2 (en) 2011-12-06

Similar Documents

Publication Publication Date Title
TWI358290B (en) Topical nepafenac formulations
ES2542728T3 (es) Composiciones farmacéuticas que tienen la biodisponibilidad deseable
DE3872029T2 (de) Rektal absorbierbare form von l-dopa.
US20090269369A1 (en) Ophthalmic Composition Comprising Xanthan Gum and Glucose
RU2009149687A (ru) Фармацевтические композиции и способы лечения сухих кератитов
JP3689123B2 (ja) ビタミンa類可溶化水性点眼剤
JP2011157388A (ja) 点眼剤
US20060257486A1 (en) Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
JP2009533462A (ja) ブリモニジンおよびチモロールの組成物
WO2007007894A1 (ja) キサンタンガムおよびテルペノイドを含有する点眼剤
JP2003206241A (ja) 眼科用剤
JP4687837B2 (ja) 眼科用組成物
JP4355574B2 (ja) 点眼剤
JP5132015B2 (ja) 点眼剤組成物
JP2007169232A (ja) 眼科用組成物
WO2013047373A1 (ja) 亜塩素酸塩を含有する水性製剤
JP5768720B2 (ja) 点眼剤
JP2001139493A (ja) 人工涙液型点眼剤組成物
WO2014192738A1 (ja) 両性イオン性ソフトコンタクトレンズ用眼科用組成物
JP2008110981A (ja) 点眼剤